Forum Pharmaceuticals Inc., of Watertown, Mass., dosed the first patient in a phase IIa proof-of-mechanism trial to evaluate FRM-0334 in patients with the ultra-orphan rare disease frontotemporal dementia with granulin mutation (FTD-GRN), an early onset and rapidly progressive neurodegenerative brain disorder that can affect behavior, cognition, language and motor skills.